Therapeutics to prevent allergic reactions


Food allergies, in particular, allergy to peanuts, are a serious public health concern that can culminate in death.There are more than 150 million people affected by allergic disease in Europe and 7 million of them suffer from food allergy. This 150 million figure is predicted to increase exponentially and it is estimated that by 2025 more than 50% of all Europeans will suffer from at least one type of allergy, with no age, social or geographical distinction.

Description of the Invention

Type I allergy is characterized by the production of immunoglobulin E (IgE) antibodies, against otherwise harmless antigens. Our novel peanut allergy therapy constitutes of IgE epitope-like peptides, that bind to specific IgEs and Ara h 2- specific IgEs on the surface of effector cells of patients with allergy to peanuts. Consequently, degranulation and segregation of mediators in the allergic reaction are prevented.

Main Advantages

Currently, there is no definitive treatment for peanut allergy. Researchers are studying ant-IgE mAb (Omalizumab) and oral immunotherapy (desensitization), but so far this approaches have not deliver a permanent cure.

Developed by
Universitv of Ljubljana, Faculty of Pharmacy and University Clinic of Respiratory and Allergic Diseases Golnik

Get in touch with us

Solutions to your challenges

More information

We use cookies (necessary, analytical and marketing) to ensure the proper functioning of our website and to improve your user experience. Click on “customize settings” to manage your preferences. For more detailed information, please check our Cookie Policy .

Guide to knowledge transfer at the University of Ljubljana.

Read more